Abstract
For protection against many infectious diseases including typhoid fever, travellers from industrialized countries who visit endemic regions in the developing world count on the efficacy of vaccination. Healthy persons can be effectively vaccinated against typhoid fever by the oral, live-attenuated S. typhi Ty21a, Vivotif Bernatm (Gilmaan et al, 1977; Woodruff et al, 1991). in immunosuppressed persons, however, it is assumed that there is an increased risk for adverse effects from vaccination with live vaccines including systemic infection with the attenuated vaccin strain. Therefore, S. typhi Ty21a is not administered to individuals immunocompromized due to, for instance, the use of high dose glucocorticosteroids, HIV-infection or hematologic malignancies.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
